BioSyent (BIOYF) Stock Price, News & Analysis

Company Overview

BioSyent Inc. is a Canadian specialty pharmaceutical company focused on acquiring, licensing, developing and commercializing pharmaceutical and healthcare products. Through its operating business, BioSyent Pharma Inc., the company targets products that address therapeutic and consumer health needs in the Canadian market.

BioSyent’s portfolio includes FeraMAX, a line of oral iron replacement products available in formulations such as FeraMAX 150 and FeraMAX Powder. The company’s business model emphasizes building and supporting established brands through regulatory, sales, marketing and distribution activities rather than manufacturing a broad range of pharmaceutical products.

BioSyent is headquartered in Canada and primarily serves Canadian patients, healthcare professionals and consumers. The company has expanded its portfolio over time through product acquisitions and licensing arrangements, although its product offerings and business activities may change as new agreements are completed.

Key Stats

• Today's Range: $11.89 to $11.97
• 50-Day Range: $10.47 to $12.41
• 52-Week Range: $7.63 to $12.41
• Volume: 880 shs
• Average Volume: 2,435 shs
• Market Capitalization: N/A
• P/E Ratio: 58.82
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BioSyent Stock Analysis - MarketRank™

BioSyent scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for BioSyent.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioSyent is 58.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.79.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioSyent is 58.82, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.01.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

BioSyent has a short interest ratio ("days to cover") of 3.17, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioSyent has recently decreased by 41.53%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioSyent does not currently pay a dividend.

Dividend Growth

BioSyent does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

BioSyent has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for BioSyent this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioSyent insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.08% of the stock of BioSyent is held by institutions.

Company Calendar

• Today: 10/11/2026
• Next Earnings (Estimated): 11/19/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:BIOYF
• CIK: N/A
• Web: www.biosyent.com
• Phone: (905) 206-0013
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 58.82
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A